American Board for Transplant Certification Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial
2017
NCT02575794
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ABTC

Active Ingredients

Drugs in Phase 2 Trials (2)

binimetinib (mektovi) (1 trial)

encorafenib (braftovi) (1 trial)

Drugs in Phase 1 Trials (2)

regadensoson (1 trial)

tetra-o-methyl nordihydroguaiaretic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Gliosarcoma (Phase 2)

Oligodendroglioma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4